SlideShare a Scribd company logo

What's New in Treatment of ER+ Breast Cancer?

Learn about the latest research and treatment for ER+ breast cancer. Erica Mayer, MD, MPH, medical oncologist with the Susan F. Smith Center for Women's Cancers, discusses new clinical trials and treatment options for this subset of breast cancer patient. This presentation was originally given on Oct. 17, 2015, at the Metastatic Breast Cancer Forum, hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass. Learn more: http://www.susanfsmith.org

1 of 31
What’s New in Treatment of ER+
Breast Cancer?
Erica L. Mayer MD MPH
Dana-Farber Cancer Institute
Invasive Breast Cancer Subsets
Defined by IHC
All Breast Cancers
Triple
negative
15%
Burstein, Goldhirsch. St Gallen 2007.
ER+
65%-75%
HER2+
15%-20%
2
Therapy for Advanced ER+ Breast Cancer
• Strong preference to begin treatment using endocrine
(hormone) therapy, unless cancer is causing significant
symptoms/problems
• At least 4+ choices (“lines”) of therapy; generally can be very
effective at controlling the cancer with minimal side effects
• New approaches are needed to improve efficacy of endocrine
therapy and delay onset of resistance
What's New in Treatment of ER+ Breast Cancer?
HOW CAN WE ENHANCE EFFICACY
OF ENDOCRINE THERAPY?
Cyclin Dependent Kinase (CDK 4/6) inhibition
• A classic feature of breast cancer is
uncontrolled growth
• In ER+ breast cancer, out-of-control
growth may be due to a failure in the
braking system: overactive CDK4/6
Ad

Recommended

Palbociclib in Metastatic Breast Cancer
Palbociclib in Metastatic Breast CancerPalbociclib in Metastatic Breast Cancer
Palbociclib in Metastatic Breast CancerVibhay Pareek
 
The Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerThe Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerDana-Farber Cancer Institute
 
Targeted therapy in mNSCLC
Targeted therapy in mNSCLCTargeted therapy in mNSCLC
Targeted therapy in mNSCLCMauricio Lema
 
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
 
Targeted therapy in breast cancer
Targeted therapy in breast cancerTargeted therapy in breast cancer
Targeted therapy in breast cancerdr-kannan
 
Palbociclib breast cancer
Palbociclib breast cancerPalbociclib breast cancer
Palbociclib breast cancerNikos Xenidis
 
Clinical Trials for Metastatic HER2-positive Breast Cancer
Clinical Trials for Metastatic HER2-positive Breast CancerClinical Trials for Metastatic HER2-positive Breast Cancer
Clinical Trials for Metastatic HER2-positive Breast CancerDana-Farber Cancer Institute
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancerDeepika Malik
 

More Related Content

What's hot

Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017Fight Colorectal Cancer
 
Introduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyIntroduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyMohamed Abdulla
 
Neoadjuvant therapy in her2+ ca breast ver 2.0
Neoadjuvant therapy in her2+ ca breast ver 2.0Neoadjuvant therapy in her2+ ca breast ver 2.0
Neoadjuvant therapy in her2+ ca breast ver 2.0Vivek Verma
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancerMohamed Abdulla
 
Advances in management of castration resistant prostate cancer
Advances in management of castration resistant prostate cancerAdvances in management of castration resistant prostate cancer
Advances in management of castration resistant prostate cancerAlok Gupta
 
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)bkling
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancerMohamed Abdulla
 
Treatment of her2 positive breast cancer
Treatment of her2 positive breast cancerTreatment of her2 positive breast cancer
Treatment of her2 positive breast cancerManar Malik
 
Targeted therapy in ovarian cancer
Targeted therapy in ovarian cancerTargeted therapy in ovarian cancer
Targeted therapy in ovarian cancerBasalama Ali
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast CancerMohamed Abdulla
 
Dr arun Triple Negative Breast cancer Presentation
Dr arun Triple Negative Breast cancer PresentationDr arun Triple Negative Breast cancer Presentation
Dr arun Triple Negative Breast cancer PresentationArun Shahi MD,MPH
 
Targeted Therapies for Breast Cancer
Targeted Therapies for Breast CancerTargeted Therapies for Breast Cancer
Targeted Therapies for Breast CancerAnvita Bharati
 
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesChapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesNilesh Kucha
 

What's hot (20)

Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
Treatment Options Stage III Colon Cancer - CRCWebinar June 21 2017
 
Introduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyIntroduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in Oncology
 
Neoadjuvant therapy in her2+ ca breast ver 2.0
Neoadjuvant therapy in her2+ ca breast ver 2.0Neoadjuvant therapy in her2+ ca breast ver 2.0
Neoadjuvant therapy in her2+ ca breast ver 2.0
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancer
 
Advances in management of castration resistant prostate cancer
Advances in management of castration resistant prostate cancerAdvances in management of castration resistant prostate cancer
Advances in management of castration resistant prostate cancer
 
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancer
 
Journal ribo
Journal ribo Journal ribo
Journal ribo
 
Tailorx Trial
Tailorx TrialTailorx Trial
Tailorx Trial
 
Treatment of her2 positive breast cancer
Treatment of her2 positive breast cancerTreatment of her2 positive breast cancer
Treatment of her2 positive breast cancer
 
OVARIAN CA
OVARIAN CAOVARIAN CA
OVARIAN CA
 
Targeted therapy in ovarian cancer
Targeted therapy in ovarian cancerTargeted therapy in ovarian cancer
Targeted therapy in ovarian cancer
 
Cleopatra trial
Cleopatra trialCleopatra trial
Cleopatra trial
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
Tumour Agnostic Treatments
Tumour Agnostic TreatmentsTumour Agnostic Treatments
Tumour Agnostic Treatments
 
Dr arun Triple Negative Breast cancer Presentation
Dr arun Triple Negative Breast cancer PresentationDr arun Triple Negative Breast cancer Presentation
Dr arun Triple Negative Breast cancer Presentation
 
Targeted Therapies for Breast Cancer
Targeted Therapies for Breast CancerTargeted Therapies for Breast Cancer
Targeted Therapies for Breast Cancer
 
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesChapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodies
 
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptxMANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
 
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptxLANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
 

Viewers also liked

Hormonal treatment of breast cancer
Hormonal treatment of breast cancerHormonal treatment of breast cancer
Hormonal treatment of breast cancerSantam Chakraborty
 
Hormone therapy in beast cancer
Hormone therapy in beast cancerHormone therapy in beast cancer
Hormone therapy in beast cancerAshutosh Mukherji
 
ASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer ReviewASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer ReviewOSUCCC - James
 
ASCO Review- 2015 What is new in breast cancer?
ASCO Review- 2015 What is new in breast cancer?ASCO Review- 2015 What is new in breast cancer?
ASCO Review- 2015 What is new in breast cancer?OSUCCC - James
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancerguest8887a7
 
Tamoxifen Presentation
Tamoxifen PresentationTamoxifen Presentation
Tamoxifen Presentationalpatric
 
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...Dana-Farber Cancer Institute
 
Breast cancer ppt
Breast cancer pptBreast cancer ppt
Breast cancer pptdrizsyed
 
Hormone therapy in breast cancer
Hormone therapy in breast cancerHormone therapy in breast cancer
Hormone therapy in breast cancerRajib Bhattacharjee
 
Trastuzumab
TrastuzumabTrastuzumab
Trastuzumabmadurai
 
ASCO Review 2016 Colorectal Cancer
ASCO Review 2016 Colorectal CancerASCO Review 2016 Colorectal Cancer
ASCO Review 2016 Colorectal CancerOSUCCC - James
 
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer Dana-Farber Cancer Institute
 
Understanding Breast Cancer Guidelines
Understanding Breast Cancer GuidelinesUnderstanding Breast Cancer Guidelines
Understanding Breast Cancer Guidelinesfondas vakalis
 

Viewers also liked (20)

Hormonal treatment of breast cancer
Hormonal treatment of breast cancerHormonal treatment of breast cancer
Hormonal treatment of breast cancer
 
Hormone therapy in beast cancer
Hormone therapy in beast cancerHormone therapy in beast cancer
Hormone therapy in beast cancer
 
ASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer ReviewASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer Review
 
What's Hot in Breast Cancer Treatment
What's Hot in Breast Cancer TreatmentWhat's Hot in Breast Cancer Treatment
What's Hot in Breast Cancer Treatment
 
ASCO Review- 2015 What is new in breast cancer?
ASCO Review- 2015 What is new in breast cancer?ASCO Review- 2015 What is new in breast cancer?
ASCO Review- 2015 What is new in breast cancer?
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancer
 
Tamoxifen Presentation
Tamoxifen PresentationTamoxifen Presentation
Tamoxifen Presentation
 
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
 
Breast Cancer Management Update (2016)
Breast Cancer Management Update (2016)Breast Cancer Management Update (2016)
Breast Cancer Management Update (2016)
 
Breast cancer ppt
Breast cancer pptBreast cancer ppt
Breast cancer ppt
 
Hormone therapy in breast cancer
Hormone therapy in breast cancerHormone therapy in breast cancer
Hormone therapy in breast cancer
 
Trastuzumab
TrastuzumabTrastuzumab
Trastuzumab
 
Fifth Annual Metastatic Breast Cancer Forum
Fifth Annual Metastatic Breast Cancer ForumFifth Annual Metastatic Breast Cancer Forum
Fifth Annual Metastatic Breast Cancer Forum
 
Herceptin
HerceptinHerceptin
Herceptin
 
ASCO Review 2016 Colorectal Cancer
ASCO Review 2016 Colorectal CancerASCO Review 2016 Colorectal Cancer
ASCO Review 2016 Colorectal Cancer
 
Breat cancer Therapy
Breat cancer TherapyBreat cancer Therapy
Breat cancer Therapy
 
Tamoxifen
TamoxifenTamoxifen
Tamoxifen
 
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
 
Immunotherapy for Breast Cancer
Immunotherapy for Breast CancerImmunotherapy for Breast Cancer
Immunotherapy for Breast Cancer
 
Understanding Breast Cancer Guidelines
Understanding Breast Cancer GuidelinesUnderstanding Breast Cancer Guidelines
Understanding Breast Cancer Guidelines
 

Similar to What's New in Treatment of ER+ Breast Cancer?

Clinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast CancerClinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast CancerDana-Farber Cancer Institute
 
What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?bkling
 
Clinical Trials - All you need to know #CRCWebinar
Clinical Trials - All you need to know #CRCWebinarClinical Trials - All you need to know #CRCWebinar
Clinical Trials - All you need to know #CRCWebinarFight Colorectal Cancer
 
Metastatic breast cancer
Metastatic breast cancerMetastatic breast cancer
Metastatic breast cancerJyoti Sharma
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentationoncolyticsinc
 
November 2017 Corporate Presentation
November 2017 Corporate PresentationNovember 2017 Corporate Presentation
November 2017 Corporate Presentationoncolyticsinc
 
November 2017 Corporate Presentation
November 2017 Corporate PresentationNovember 2017 Corporate Presentation
November 2017 Corporate Presentationoncolyticsinc
 
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Pharma Intelligence
 
Clinical trials
Clinical trialsClinical trials
Clinical trialsriancopper
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentationoncolyticsinc
 
MedicalResearch.com: Medical Research Exclusive Interviews April 28 2015
MedicalResearch.com:  Medical Research Exclusive Interviews April 28  2015MedicalResearch.com:  Medical Research Exclusive Interviews April 28  2015
MedicalResearch.com: Medical Research Exclusive Interviews April 28 2015Marie Benz MD FAAD
 
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingdianecleverley
 
CLINICAL TRIAL.pptx
CLINICAL TRIAL.pptxCLINICAL TRIAL.pptx
CLINICAL TRIAL.pptxPuzzlePlay
 
Seriously Ill Patients Access To Experimental Therapies
Seriously  Ill  Patients   Access To  Experimental  TherapiesSeriously  Ill  Patients   Access To  Experimental  Therapies
Seriously Ill Patients Access To Experimental TherapiesRyan Witt
 
Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16
Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16
Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16Fight Colorectal Cancer
 
ADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptxADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptxnann22
 

Similar to What's New in Treatment of ER+ Breast Cancer? (20)

Clinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast CancerClinical Trials for Metastatic Triple-Negative Breast Cancer
Clinical Trials for Metastatic Triple-Negative Breast Cancer
 
What Is a Phase I Clinical Trial?
What Is a Phase I Clinical Trial?What Is a Phase I Clinical Trial?
What Is a Phase I Clinical Trial?
 
What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?
 
Clinical Trials - All you need to know #CRCWebinar
Clinical Trials - All you need to know #CRCWebinarClinical Trials - All you need to know #CRCWebinar
Clinical Trials - All you need to know #CRCWebinar
 
Metastatic breast cancer
Metastatic breast cancerMetastatic breast cancer
Metastatic breast cancer
 
The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...
The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...
The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...
 
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentation
 
November 2017 Corporate Presentation
November 2017 Corporate PresentationNovember 2017 Corporate Presentation
November 2017 Corporate Presentation
 
November 2017 Corporate Presentation
November 2017 Corporate PresentationNovember 2017 Corporate Presentation
November 2017 Corporate Presentation
 
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentation
 
MedicalResearch.com: Medical Research Exclusive Interviews April 28 2015
MedicalResearch.com:  Medical Research Exclusive Interviews April 28  2015MedicalResearch.com:  Medical Research Exclusive Interviews April 28  2015
MedicalResearch.com: Medical Research Exclusive Interviews April 28 2015
 
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
 
CLINICAL TRIAL.pptx
CLINICAL TRIAL.pptxCLINICAL TRIAL.pptx
CLINICAL TRIAL.pptx
 
ASCO Poster
ASCO PosterASCO Poster
ASCO Poster
 
Seriously Ill Patients Access To Experimental Therapies
Seriously  Ill  Patients   Access To  Experimental  TherapiesSeriously  Ill  Patients   Access To  Experimental  Therapies
Seriously Ill Patients Access To Experimental Therapies
 
Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16
Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16
Clinical Trials and Cooperative Group Studies - WIMR @FightCRC @CRCRes16
 
ADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptxADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptx
 

More from Dana-Farber Cancer Institute

Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer Dana-Farber Cancer Institute
 
How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?Dana-Farber Cancer Institute
 
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Dana-Farber Cancer Institute
 
Surgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and WhySurgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and WhyDana-Farber Cancer Institute
 
Primary Systemic Therapy for Inflammatory Breast Cancer
Primary Systemic Therapy for Inflammatory Breast CancerPrimary Systemic Therapy for Inflammatory Breast Cancer
Primary Systemic Therapy for Inflammatory Breast CancerDana-Farber Cancer Institute
 
7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer Patients7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer PatientsDana-Farber Cancer Institute
 

More from Dana-Farber Cancer Institute (20)

Exercise Tips for Cancer Patients
Exercise Tips for Cancer Patients Exercise Tips for Cancer Patients
Exercise Tips for Cancer Patients
 
Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer Personal Finance Tips for Young Adults with Cancer
Personal Finance Tips for Young Adults with Cancer
 
5 Things to Know About Glioblastomas
5 Things to Know About Glioblastomas5 Things to Know About Glioblastomas
5 Things to Know About Glioblastomas
 
How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?How are Adult and Childhood Leukemia Alike and Different?
How are Adult and Childhood Leukemia Alike and Different?
 
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...
 
Healthy Living After A Breast Cancer Diagnosis
Healthy Living After A Breast Cancer DiagnosisHealthy Living After A Breast Cancer Diagnosis
Healthy Living After A Breast Cancer Diagnosis
 
Signs and Symptoms of Prostate Cancer
Signs and Symptoms of Prostate CancerSigns and Symptoms of Prostate Cancer
Signs and Symptoms of Prostate Cancer
 
6 Common Types of Pediatric Brain Tumors
6 Common Types of Pediatric Brain Tumors6 Common Types of Pediatric Brain Tumors
6 Common Types of Pediatric Brain Tumors
 
Soft Tissue Sarcomas: Symptoms and Risk Factors
Soft Tissue Sarcomas: Symptoms and Risk FactorsSoft Tissue Sarcomas: Symptoms and Risk Factors
Soft Tissue Sarcomas: Symptoms and Risk Factors
 
10 Tips for Easing Chemo-Related Fatigue
10 Tips for Easing Chemo-Related Fatigue10 Tips for Easing Chemo-Related Fatigue
10 Tips for Easing Chemo-Related Fatigue
 
Surgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and WhySurgery for Inflammatory Breast Cancer: How and Why
Surgery for Inflammatory Breast Cancer: How and Why
 
Radiation Therapy for Inflammatory Breast Cancer
Radiation Therapy for Inflammatory Breast CancerRadiation Therapy for Inflammatory Breast Cancer
Radiation Therapy for Inflammatory Breast Cancer
 
Primary Systemic Therapy for Inflammatory Breast Cancer
Primary Systemic Therapy for Inflammatory Breast CancerPrimary Systemic Therapy for Inflammatory Breast Cancer
Primary Systemic Therapy for Inflammatory Breast Cancer
 
What Cancers Should Men Be Screened For?
What Cancers Should Men Be Screened For?What Cancers Should Men Be Screened For?
What Cancers Should Men Be Screened For?
 
Five Common Types of Brain Tumors
Five Common Types of Brain TumorsFive Common Types of Brain Tumors
Five Common Types of Brain Tumors
 
Signs and Symptoms of Multiple Myeloma
Signs and Symptoms of Multiple MyelomaSigns and Symptoms of Multiple Myeloma
Signs and Symptoms of Multiple Myeloma
 
7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer Patients7 Ways Integrative Therapies Can Help Cancer Patients
7 Ways Integrative Therapies Can Help Cancer Patients
 
Five Things You Need to Know About Colon Cancer
Five Things You Need to Know About Colon CancerFive Things You Need to Know About Colon Cancer
Five Things You Need to Know About Colon Cancer
 
What You Should Know About Cervical Cancer
What You Should Know About Cervical CancerWhat You Should Know About Cervical Cancer
What You Should Know About Cervical Cancer
 
Making A New Treatment Decision
Making A New Treatment DecisionMaking A New Treatment Decision
Making A New Treatment Decision
 

Recently uploaded

Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxDr. Dheeraj Kumar
 
Anesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptxAnesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptxhrowshan
 
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...Dr. Madduru Muni Haritha
 
CHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating NeuropathiesCHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating NeuropathiesMohamed AbdElhady
 
Renal Regulation of Potassium, Calcium, Magnesium and Phosphorus
Renal Regulation of Potassium, Calcium, Magnesium and PhosphorusRenal Regulation of Potassium, Calcium, Magnesium and Phosphorus
Renal Regulation of Potassium, Calcium, Magnesium and PhosphorusMedicoseAcademics
 
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.vrchk912
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...Abhinav S
 
ABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdf
ABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdfABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdf
ABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdfAbdurahmanRafeeq
 
Seminario biología molecular Kevin Duque
Seminario biología molecular Kevin DuqueSeminario biología molecular Kevin Duque
Seminario biología molecular Kevin Duquekevinestebanduque
 
Cell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfCell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfMedicoseAcademics
 
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...Abhinav S
 
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...bkling
 
SEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdf
SEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdfSEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdf
SEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdfmarlonduqueupb
 
Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)MedicoseAcademics
 
Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...
Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...
Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...leejalashrestha2
 
Autism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxAutism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxScripted Symptoms
 
Seminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez RamírezSeminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez Ramírezmanuelaalvarezr
 
Presentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementPresentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementeshasmalik27
 
seminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaaseminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaasofialopezvalencia
 

Recently uploaded (20)

Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptx
 
Anesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptxAnesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptx
 
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
 
CHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating NeuropathiesCHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
 
Renal Regulation of Potassium, Calcium, Magnesium and Phosphorus
Renal Regulation of Potassium, Calcium, Magnesium and PhosphorusRenal Regulation of Potassium, Calcium, Magnesium and Phosphorus
Renal Regulation of Potassium, Calcium, Magnesium and Phosphorus
 
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
 
ABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdf
ABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdfABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdf
ABDULRAHMAN AL RAFIQ UPDATED MANAGEMENT OF ACUTE PULMONARY EMBOLISM .pdf
 
Seminario biología molecular Kevin Duque
Seminario biología molecular Kevin DuqueSeminario biología molecular Kevin Duque
Seminario biología molecular Kevin Duque
 
Cell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfCell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdf
 
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
 
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
 
SEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdf
SEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdfSEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdf
SEMINARIO VIH BIOLOGIA MOLECULAR PDF.pdf
 
Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)
 
Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...
Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...
Bursitis is inflammation or irritation of a bursa sac. Bursae are small fluid...
 
Autism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxAutism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptx
 
Seminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez RamírezSeminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez Ramírez
 
Introduction Endocrinology class -2.pptx
Introduction Endocrinology class -2.pptxIntroduction Endocrinology class -2.pptx
Introduction Endocrinology class -2.pptx
 
Presentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementPresentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic management
 
seminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaaseminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaa
 

What's New in Treatment of ER+ Breast Cancer?

  • 1. What’s New in Treatment of ER+ Breast Cancer? Erica L. Mayer MD MPH Dana-Farber Cancer Institute
  • 2. Invasive Breast Cancer Subsets Defined by IHC All Breast Cancers Triple negative 15% Burstein, Goldhirsch. St Gallen 2007. ER+ 65%-75% HER2+ 15%-20% 2
  • 3. Therapy for Advanced ER+ Breast Cancer • Strong preference to begin treatment using endocrine (hormone) therapy, unless cancer is causing significant symptoms/problems • At least 4+ choices (“lines”) of therapy; generally can be very effective at controlling the cancer with minimal side effects • New approaches are needed to improve efficacy of endocrine therapy and delay onset of resistance
  • 5. HOW CAN WE ENHANCE EFFICACY OF ENDOCRINE THERAPY?
  • 6. Cyclin Dependent Kinase (CDK 4/6) inhibition • A classic feature of breast cancer is uncontrolled growth • In ER+ breast cancer, out-of-control growth may be due to a failure in the braking system: overactive CDK4/6
  • 7. What’s Hot for ER+ Breast Cancer? CDK 4/6 inhibition • CDK 4/6 Inhibition: – puts the brakes on cell growth – pushes cancer cells towards cell death
  • 8. Palbociclib (Ibrance) • Palbociclib: oral inhibitor of CDK 4/6 • Taken daily, 3 weeks on, 1 week off • Most common toxicities: low white blood cell count (but no infections), fatigue, mild hair thinning
  • 9. PALOMA-1 Trial: Schema • First randomized trial of palbociclib in breast cancer (phase II) • Women with newly diagnosed metastatic breast cancer were randomized to first-line therapy with letrozole alone, or letrozole + palbociclib Letrozole Palbociclib + Letrozole • Metastatic breast cancer • ER+/HER2- • First line
  • 10. PALOMA-1 Trial: Results • Women taking the 2 medications had substantially better disease control that those taking the 1 medication • The combination arm was well tolerated
  • 11. PALOMA-3 Study Design • Larger trial in women whose cancer previously showed resistance to endocrine therapy (Phase III) Placebo + Fulvestrant Palbociclib + Fulvestrant• Metastatic breast cancer • ER+/HER2- • Tumor has shown resistance to endocrine therapy
  • 12. PALOMA-3 Results • Combination arm again did substantially better than fulvestrant and placebo • Toxicity profile very similar to PALOMA-1 • Validates activity of palbociclib seen in PALOMA-1 • No new toxicity signals with the drug • Await results of PALOMA-2: similar to PALOMA-1 but a larger trial
  • 13. IF IT WORKS IN ADVANCED DISEASE, WILL IN WORK EARLIER ON TO PREVENT METASTATIC BREAST CANCER?
  • 14. PALLAS: Phase III Randomized Trial of Adjuvant Endocrine Therapy +/- Palbociclib Patient Population •N = 4600 •HR+ and HER2- • Stage II or III Arm A Palbociclib (2 yrs) + Endocrine Treatment (5+ yrs) Arm B Endocrine treatment (5+ yrs) R A N D O M I Z E 1:1 Survival/Disease Follow-up Arm A: palbociclib at a dose of 125 mg once daily, Day 1-21 in a 28-day cycle for total duration of 2 years, in addition to standard adjuvant endocrine therapy Arm B: standard adjuvant endocrine therapy (AI, tamoxifen) Opening 11/2015….
  • 15. HOW CAN WE OVERCOME RESISTANCE TO ENDOCRINE THERAPY?
  • 16. Dual Targeting An endocrine sensitive cell depends on the estrogen receptor nucleus Cancer cell Estrogen receptor
  • 17. Dual Targeting In setting of endocrine resistance, other pathways are activated nucleus Cancer cell Estrogen receptor Growth factor receptor mTOR PI3K
  • 18. Dual Targeting In setting of endocrine resistance, dual targeting may be important nucleus Cancer cell Estrogen receptor Growth factor receptor mTOR PI3K
  • 19. BOLERO-2 Study Design • Trial of mTOR inhibitor added to exemestane (AI) in endocrine resistant ER+ advanced breast cancer Placebo + Exemestane Everolimus + Exemestane• Metastatic breast cancer • ER+/HER2- • Tumor has shown resistance to endocrine therapy
  • 20. BOLERO-2 Results • Combination arm had better cancer control than exemestane and placebo • Toxicity profile: mouthsores, fatigue diarrhea, can be controlled with dose reduction • Enhancement of activity in setting of resistance validates laboratory model • Results of BOLERO-2 led to FDA approval of everolimus for breast cancer in July 2012 • Currently under study in the adjuvant setting
  • 21. What About Targeting PI3K? • Laboratory work suggests PI3K inhibitor + endocrine therapy is synergistic • Almost 40-45% of ER+ breast cancer has a PIK3CA mutation – does this predict a cancer will be sensitive? • Trials of 1st generation PI3K inhibitors did not show enough signal to move forward. • 2nd generation agents are more selective (“alpha specific”) and may show greater activity 21 MCF-7 (E545K) 1. Miller et al. JCO 2010 2. Baselga et al. NEJM 2012; Bachelot et al. JCO 2012 3. Raynaud et al., MCT 2009
  • 22. Alpha Specific PI3K Inhibitors are Now in Phase III Trials! SANDPIPER trial Normal Assignment of treatment by presence of mutation: an example of “precision medicine”
  • 23. How Can We Do Better? Participate in Trials! • “One reason I chose to participate in a clinical trial was to help women with triple-negative breast cancer. It is thanks to women who have enrolled in clinical trials that we have the treatments that give us hope.” – Natalia (LBBC, Guide to Understanding TNBC)
  • 24. How Can We Do Better? Participate in Trials! • Clinical trials exist for patients at any step of their breast cancer journey; trials are a part of the continuum of care • There are benefits to being on a trial! – a larger treatment team – possible exposure to cutting edge new medications – helping other patients with breast cancer • None of the advances in breast cancer could have happened without patients volunteering to be in trials!
  • 25. What are clinical trial phases? Clinical trials are conducted in a series of steps (phases) - each phase is designed to answer a separate research question. • Phase I: Testing a new treatment in a small group to evaluate safety, dose, and side effects. • Phase II: Evaluating within a larger group the efficacy and safety of a new treatment • Phase III: A comparison study in a large group to determine if a new treatment works better than standard therapy. These trials typically involve randomization and may have a placebo; the data from a phase 3 trial can be used for FDA drug approval. FDA approval
  • 26. How Do I Enter a Trial? • Your provider will discuss with you trials of interest, review rationale, as well as risks and benefits • A research RN will review a consent form with you, which describes the structure and details of the trial • After a consent is signed, there is a “screening” period to determine if you are eligible • When eligibility is confirmed, then you register and can begin trial therapy
  • 27. Clinical Trials: FAQs • If I consent to a trial, do I have to stay on it? – You can leave a trial at any time if either you or your provider thinks being on the trial is no longer in your best interest • Will I have to pay more to be on a trial? – All normal procedures are billed to insurance; anything beyond normal care is paid for by the trial. There should be no “upcharge” for being in a trial • Is being on a trial busy? – Each trial is different and has a different schedule • Will I know what medicine I am getting? I don’t want a placebo. – In most trials, both patient and provider know exactly what treatment is being given. – Some larger trials use randomization and placebos, and in some cases neither patient nor provider know identity of study drug. – But in almost every trial with placebo, at minimum a patient receives best standard of care.
  • 28. How to learn about trials? Or ask your provider…
  • 29. Current Trials at DFCI for Advanced ER+ Breast Cancer (as of 10/15/15) Protocol # Short Title 15-060 Palbociclib + Bazedoxifene 15-058 Abemaciclib in Patients with Brain Metastases secondary to HR+ Breast Cancer 14-569 Ph I SRN-927 in Postmenopausal ER+ MBC 14-565 Ph III Rand. DB LEE011 or Placebo in comb. w/TAM + Goserlin or NSAI + Goserlin for Premenopausal BC (MONALEESA-7) 14-518 Fulvestrant +/- Abemaciclib 14-098 LEE011/Fulvestrant/BYL719/ BKM120 for BC 14-070 LY2835219 + Endocrine for HR+ MBC 13-157 BYL719+Letrozole in HR+ BC 11-477 Faslodex +/- Ganetespib for HR+ MBC 11-010 GDC0032 + Endocrine 11-208 Cabozantinib + Fulvestrant for MBC
  • 30. Conclusions • Incredibly exciting work going on in breast cancer research for ER+ breast cancer – New targets – Moving away from chemotherapy – Learning a tremendous amount from each biopsy • Future progress depends on.....Making every woman count!

Editor's Notes

  1. SCA-14 SABCS V6 02-13-07.pptSCA-10 breast cancer slides_8-21-06.ppt
  2. Non-specific PI3K inhibitor